NetworkNewsBreaks – CytomX Therapeutics, Inc. (NASDAQ: CTMX) Featured in Mizuho Securities Research Report
CytomX Therapeutics (NASDAQ: CTMX) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “With the announcement of the advancement of two Probody-enabled candidates by partner BMY (NC), we see greater visibility for CTMX's pipeline in 2020. Our thesis has been that the shares could see valuation expansion with greater visibility on clinical candidates and we believe we are seeing this, particularly with today's acknowledgement of the advancement of two BMY candidates. We see this as incrementally positive to the previous update that included advancement plans for CX-072, CX-2009, and the disclosure…







